NEWS

March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women

COMPANY
PIPELINE
- OREXA
- LOREXYS
- S1B-307
- S1B-3006
A New Vision for addressing Sexual Wellness
NEWSROOM
- PRESS RELEASES
- MEDIA COVERAGE
INVESTORS
- LOGIN
CONTACT US

P882wqIgaSCsTPMWRq0gxa0n1T0FJ1cmzsa4NU11pbc

‹ Return to P882wqIgaSCsTPMWRq0gxa0n1T0FJ1cmzsa4NU11pbc

September 26, 2013 admin — No Comments

Leave a Reply Cancel reply

Your email address will not be published.

Comment

Name *

E-mail *

Website

Save my name, email, and website in this browser for the next time I comment.

Notify me of new posts by email.

Δ

March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder

Recent Comments

Archives

March 2021
December 2019
January 2019
December 2018
April 2016
February 2016
December 2015
November 2015
June 2015
March 2014
October 2013
August 2013
July 2013
May 2013
February 2013
May 2012
April 2012
March 2012
February 2012
October 2011

Categories

Erectile Dysfunction
EVENTS
FDA
FSD
HSDD
LOREXYS
MEDIA COVERAGE
NEWS
OREXA
PRESS RELEASES
S1B-3006
S1P-205
scientific publications

Meta

Log in
Entries feed
Comments feed
WordPress.org

CONTACT US
SITE MAP
Terms of Use

© S1 biopharma Inc.

S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St.
46th Floor
New York City, NY 10007
Email: info@s1biopharma.com